Mein Warenkorb

Transferrin

Transferrin Produktliste

  • Attribut

    Protein (7)

  • Produktbibliothek

    Online (7)

  • Spezies

    Mouse (2)Human (3)Rhesus macaque (2)

  • Etikett

    Mouse IgG Fc Tag (1)His Tag & Avi Tag (3)His Tag (2)Tag Free (1)

  • Marker

    Unconjugated (4)Biotin-labeled (3)

Transferrin Molekülhintergrund

Transferrin is also known as Serotransferrin, Beta-1 metal-binding globulin, TF, and is iron-binding blood plasma glycoproteins that control the level of free iron in biological fluids. Although iron bound to transferrin is less than 0.1% (4 mg) of the total body iron, it is the most important iron pool, with the highest rate of turnover (25 mg/24 h). The affinity of transferrin for Fe(III) is extremely high (1023 M−1 at pH 7.4) but decreases progressively with decreasing pH below neutrality.When not bound to iron, it is known as "apo-transferrin”. In humans, transferrin consists of a polypeptide chain containing 679 amino acids. It is a complex composed of alpha helices and beta sheets to form two domains (the first situated in the N-terminus and the second in the C-terminus). The N- and C- terminal sequences are represented by globular lobes and between the two lobes is an iron-binding site. The liver is the main source of manufacturing transferrin, but other sources such as the brain also produce this molecule . Transferrin is also associated with the innate immune system. Transferrin is found in the mucosa and binds iron, thus creating an environment low in free iron that impedes bacteria survival in a process called iron withholding. The level of transferrin decreases in inflammation. The metal binding properties of transferrin have a great influence on the biochemistry of plutonium in humans. Transferrin has a bacteriocidal effect on bacteria, in that it makes Fe3+ unavailable to the bacteria.Carbohydrate deficient transferrin increases in the blood with heavy ethanol consumption and can be monitored via laboratory testing.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Human apotransferrin (Sanquin Blood Supply Foundation)Phase 3 ClinicalSanquin Plasma Products BvIron Metabolism Disorders; beta-Thalassemia
Details
Delpacibart eteddesiranAOC-1001; AOC 1001Phase 3 ClinicalAvidity Biosciences IncMyotonic Disorders; Genetic Diseases, Inborn; Musculoskeletal Diseases; Muscular Disorders, Atrophic; Myotonic Dystrophy; Muscular Atrophy; Heredodegenerative Disorders, Nervous System; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Neurodegenerative Diseases; Myotonia
Details
CX-2029ABBV-2029; ABBV-CX-2029; CX-2029Phase 2 ClinicalAbbvie Inc, Cytomx Therapeutics IncSolid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung
Details
DYNE-251DYNE251Phase 2 ClinicalDyne Therapeutics IncMuscular Dystrophy, Duchenne
Details
JR-446JR-446Phase 2 ClinicalJcr Pharmaceuticals Co Ltd, Medipal Holdings CorpMucopolysaccharidosis III
Details
JR-441JR-441Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis III
Details
Lepunafusp alfaJR-171Phase 2 ClinicalJcr Pharmaceuticals Co LtdMucopolysaccharidosis I
Details
PPMX-T003PPMX-T003Phase 2 ClinicalPerseus Proteomics IncLeukemia; Polycythemia Vera
Details
TrontinemabRO-7126209; RG-6102Phase 2 ClinicalF. Hoffmann-La Roche LtdAlzheimer Disease
Details
INA-03INA03Phase 1 ClinicalInatherysLeukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute
Details
KK-2260KK2260; KK-2260Phase 1 ClinicalKyowa Kirin Co LtdSolid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
ABX-1100ABX-1100Phase 1 ClinicalAro Biotherapeutics CoGlycogen Storage Disease Type II
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pabinafusp alfaJR-141ApprovedJcr Pharmaceuticals Co LtdJapanMucopolysaccharidosis IIJcr Pharmaceuticals Co Ltd2021-03-23Mucopolysaccharidosis II
Details
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns